# AstraZeneca: Phase 1 study completed, 10 enrolled (Kidney Failure)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin |
| NCT ID | NCT07754331 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Kidney Failure |
| Intervention types | drug |
| Target enrollment | 10 |
| Site countries | United States |
| Posted | 2026-08-10 |
| Planned start | 2026-08-06 |
| Event | Completed |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-20 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07754331). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.